Supernus' acquistion brings a new Food and Drug Administration (FDA)-approved drug to its portfolio of Parkinson's disease treatments
Article Originally Published by Rockville Nights on October 12, 2021
Rockville-based Supernus Pharmaceuticals announced Monday that it is acquiring Adamas Pharmaceuticals, adding to its portfolio of Parkinson’s disease treatments. The deal will bring Adamas’ GOCOVRI (amantadine) extended release capsules, the first and only U.S. Food and Drug Administration (FDA)-approved drug for the treatment of both OFF and dyskinesia in patients with Parkinson’s disease who are receiving levodopa-based therapy; and Osmolex ER® (amantadine) extended release tablets, which is FDA-approved for the treatment of Parkinson’s disease, and drug-induced extrapyramidal reactions in adults.
The deal is a financial win for Adamas stockholders, and will expand the revenue base and cash flow of Supernus. “This acquisition represents a significant step to further build a strong and diverse Parkinson’s disease portfolio, and aligns with our focus of acquiring value-enhancing, clinically-differentiated medicines to treat CNS diseases,” Jack Khattar, President and CEO of Supernus Pharmaceuticals said in a statement. “We have a proven track record of strong commercial execution, and look forward to building on GOCOVRI’s growth momentum so that more patients can benefit from access to Adamas’ innovative neurological therapies.”
Once again, biotech – along with residential housing construction – remain the only bright spots in an otherwise moribund and stagnant Montgomery County economy. This is largely because the smart decisions that led to the growth of Montgomery’s biotech sector were made before those who wrecked the County’s economy took office in 2002, 2006 and 2010. Supernus is located at 9715 Key West Avenue in Rockville.